• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Determining Appropriate Duration of Treatment

Video

Immunotherapeutic agents have demonstrated effectiveness at delivering sustained treatment responses; however, these agents are associated with substantial costs. Furthermore, prolonged use of immunotherapy can increase the likelihood that a patient will experience treatment toxicities.

Richard W. Joseph, MD, explains how clinical studies designed to assess appropriate duration of immunotherapy treatment can help reduce these patient burdens.

Dr Joseph notes that clinical trials of immunotherapy in different types of cancer have demonstrated durable response rates. Keeping patients on immunotherapy for a long period of time may not always be necessary, and studies that evaluate the appropriate duration of treatment with immunotherapeutic agents are needed. If cancer recurs, he adds, patients may still respond when immunotherapy is restarted.

By appropriately limiting the length of treatment with immunotherapy based on data from clinical trials, healthcare professionals can reduce the cost burden and the likelihood of experiencing treatment toxicities, Dr Joseph remarks.


Related Videos
Gordon Crofoot, MD, PA
Screenshot of Coral Omene, MD, PhD
Dr Brian Slomovitz
4 experts are featured in this series.
2 experts in this video
2 experts in this video
4 experts are featured in this series.
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Adam Colborn, JD, associate vice president for congressional affairs, Academy of Managed Care Pharmacy (AMCP)
ASCO 2025
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.